Clinical Trials Browser

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT00547534 2015-08-06

BVR

Phase 2 Completed

31 enrolled 9 charts

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00651781 2013-02-28

Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia

Phase 1/2 Completed

40 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00536575 2013-02-27

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Phase 1/2 Completed

13 enrolled 5 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT00335348 2013-01-09

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Phase 2 Completed

101 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00652041 2011-09-19

TaCyDexVMP7

Phase 4 Completed

40 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00602511 2011-02-09

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Phase 3 Completed

300 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00509379 2011-01-28

LYM-2023

Phase 2 Completed

48 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT00136591 2010-10-26

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Phase 2 Terminated

87 enrolled

Lymphoid

Lymphoma, Follicular, Recurrence

NCT00382954 2010-09-29

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

Phase 1 Completed

55 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00508209 2010-06-22

Bortezomib and High-dose Melphalan at Myeloma Relapse

Phase 2 Unknown

50 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00148018 2008-07-10

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

Phase 2 Terminated

37 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

NCT00261612 2006-10-18

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Phase 2 Unknown

16 enrolled

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Clinical Trials

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

FIL_DALYA

BORTEM-17

TEAM

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

(R-HAD)

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

BVR

Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

TaCyDexVMP7

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

LYM-2023

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

Bortezomib and High-dose Melphalan at Myeloma Relapse

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma